Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CRISPR Therapeutics AGLTS:0VRQ -1.23%34 3-1 Month Momentum % is -0.92% as of Aug. 15, 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 34/100 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,388 Biotechnology companies, CRISPR Therapeutics AG ranks better than 58.43% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-15), CRISPR Therapeutics AG's 3-1 Month Momentum % is -0.92%.
The industry rank for CRISPR Therapeutics AG's 3-1 Month Momentum % or its related term are showing as below:
LTS:0VRQ's 3-1 Month Momentum % is ranked better than 58.43% of 1388
companies
in the Biotechnology industry
Industry Median: -8.13
vs LTS:0VRQ: -0.92
CRISPR Therapeutics AG (LTS:0VRQ) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
CRISPR Therapeutics AG 3-1 Month Momentum % Related Terms
LTS:0VRQ vs MANE, EWTX, CAI: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's 3-1 Month Momentum % falls into.
CRISPR Therapeutics AG (LTS:0VRQ) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (LTS:0VRQ) has a 3-1 Month Momentum % of -0.92% as of Aug. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CRISPR Therapeutics AG and its competitors. According to the industry distribution chart, CRISPR Therapeutics AG ranks #577 out of 1388 companies in the Biotechnology industry, placing it in the top 41.6%.
Is CRISPR Therapeutics AG's 3-1 Month Momentum % too high?
CRISPR Therapeutics AG's current 3-1 Month Momentum % is -0.92%. Based on the distribution chart, CRISPR Therapeutics AG ranks #577 out of 1388 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CRISPR Therapeutics AG has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's 3-1 Month Momentum % compare to MANE and EWTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #577 out of 1388 companies for 3-1 Month Momentum %. This puts CRISPR Therapeutics AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current 3-1 Month Momentum % is -0.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The current 3-1 Month Momentum % is -0.92%. CRISPR Therapeutics AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current 3-1 Month Momentum % is -0.92% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
34GF Score
Get the complete analysis for LTS:0VRQ
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
